We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+25.49%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$918M
AUM Growth
+$52.7M
Cap. Flow
-$46.8M
Cap. Flow %
-5.1%
Top 10 Hldgs %
48.26%
Holding
70
New
15
Increased
16
Reduced
21
Closed
16

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$38.1M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$29.8M
3
AZN icon
AstraZeneca
AZN
+$18.5M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$18.5M
5
BIIB icon
Biogen
BIIB
+$13.9M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$39.5M
2
HCA icon
HCA Healthcare
HCA
+$23.2M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$20.9M
4
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$18.8M
5
WCG
Wellcare Health Plans, Inc.
WCG
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.78%
2 Miscellaneous 9.3%
3 Technology 2.51%
4 Communication Services 1.69%
5 Financials 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$57.2M 6.23%
6,875,274
+1,168,368
+20% +$8.02M
ARRY
2
DELISTED
Array Biopharma Inc
ARRY
$56.1M 6.11%
11,858,294
+3,516,249
+42% +$13.9M
BHC icon
3
Bausch Health
BHC
$2.36B
$48.4M 5.27%
338,477
+5,910
+2% +$795K
CMRX
4
DELISTED
Chimerix, Inc.
CMRX
$46.6M 5.07%
1,157,184
+36,152
+3% +$1.22M
RAD
5
DELISTED
Rite Aid Corporation
RAD
$45.4M 4.94%
301,937
+38,901
+15% +$4.32M
CLVS
6
DELISTED
Clovis Oncology, Inc.
CLVS
$40.4M 4.4%
721,632
-62,827
-8% -$3.3M
RCPT
7
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$38.3M 4.17%
312,736
-127,142
-29% -$12.9M
CELG
8
DELISTED
Celgene Corp
CELG
$38.3M 4.17%
342,349
-27,051
-7% -$2.85M
ADVM
9
DELISTED
Adverum Biotechnologies
ADVM
$37.8M 4.11%
69,907
-39
-0.1% -$15K
GILD icon
10
Gilead Sciences
GILD
$181B
$34.7M 3.78%
+368,615
New +$38.1M
SGEN
11
DELISTED
Seagen Inc. Common Stock
SGEN
$31.6M 3.44%
983,966
+855,736
+667% +$29.8M
TRIV
12
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$22.1M 2.4%
1,755,568
+4,050
+0.2% +$55.2K
ZSPH
13
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$21.8M 2.37%
524,702
+50,570
+11% +$2M
TVTY
14
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$21.2M 2.31%
1,068,489
+41,986
+4% +$686K
LAB icon
15
Standard BioTools
LAB
$252M
$20.6M 2.24%
610,442
+50,820
+9% +$1.44M
AZN icon
16
AstraZeneca
AZN
$252B
$18.2M 1.98%
+258,305
New +$18.5M
MCK icon
17
McKesson
MCK
$104B
$18.2M 1.98%
87,523
-74,242
-46% -$15.1M
PBYI icon
18
Puma Biotechnology
PBYI
$468M
$17.8M 1.93%
93,865
+42,840
+84% +$9.5M
NSTG
19
DELISTED
NanoString Technologies, Inc.
NSTG
$17.6M 1.92%
1,266,538
-187,117
-13% -$2.28M
ITCI
20
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$17.5M 1.9%
990,810
-12,686
-1% -$198K
BLCM
21
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$17.3M 1.88%
+86,081
New +$18.5M
NUVA
22
DELISTED
NuVasive, Inc.
NUVA
$16.9M 1.84%
358,679
-139,762
-28% -$5.83M
HNT
23
DELISTED
HEALTH NET INC
HNT
$16.5M 1.8%
309,045
-25,890
-8% -$1.27M
PRQR icon
24
ProQR Therapeutics
PRQR
$323M
$15.7M 1.71%
751,171
-14,061
-2% -$213K
INSM icon
25
Insmed
INSM
$25.9B
$15.7M 1.71%
1,012,371
-78,253
-7% -$1.11M
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2014 Portfolio in Review

As of Q4 2014, Redmile Group held 70 positions worth $918M, up 6.1% from $866M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group withdrew a net $46.8M in Q4 2014, closing 16 positions and reducing 21 holdings. Its most notable exit was Allergan plc, an estimated $39.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 76% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Redmile Group opened a new position in Gilead Sciences worth $34.7M.

  • Redmile Group's largest Q4 2014 buy was Gilead Sciences: 368,615 shares worth $34.7M.
  • Redmile Group added most to Seagen Inc. Common Stock in Q4 2014, an estimated $29.8M increase.
  • Redmile Group's biggest Q4 2014 reduction was Wellcare Health Plans, Inc., cutting an estimated $15.3M.
  • Redmile Group fully exited Allergan plc in Q4 2014, selling an estimated $39.5M.
  • Redmile Group's ten largest holdings make up 48% of its $918M portfolio in Q4 2014.
  • Redmile Group opened 15 new positions and closed 16 in Q4 2014.
  • Redmile Group's portfolio value rose 6.1% quarter-over-quarter to $918M.

Based on Redmile Group's 13F filing for Q4 2014, filed 18 Feb 2015.